S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:AEZS

Aeterna Zentaris - AEZS News Today

$5.57
+0.39 (+7.53%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.13
$5.75
50-Day Range
$4.25
$6.32
52-Week Range
$4.11
$24.38
Volume
150,433 shs
Average Volume
48,784 shs
Market Capitalization
$27.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Get Aeterna Zentaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

AEZS Media Mentions By Week

AEZS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AEZS
News Sentiment

1.18

0.63

Average
Medical
News Sentiment

AEZS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AEZS Articles
This Week

3

0

AEZS Articles
Average Week



SourceHeadline
MarketBeat logoAeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
americanbankingnews.com - August 15 at 1:35 AM
MarketBeat logoAeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - August 11 at 1:54 AM
MarketBeat logoAeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.com
americanbankingnews.com - August 2 at 5:23 AM
finanznachrichten.de logoAeterna Zentaris Inc: Aeterna Zentaris Announces Effective Date of Share Consolidation
finanznachrichten.de - July 19 at 7:56 AM
finance.yahoo.com logoAeterna Zentaris to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 9 at 8:34 AM
seekingalpha.com logoAeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe
seekingalpha.com - May 25 at 11:14 AM
investing.com logoAeterna Zentaris Reports Q1 Net Loss of $2.6M, Provides Business Outlook
investing.com - May 11 at 9:38 AM
finance.yahoo.com logoAeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
finance.yahoo.com - May 11 at 9:38 AM
seekingalpha.com logoAeterna Zentaris gets European patent related to macimorelin to detect growth hormone deficiency
seekingalpha.com - April 19 at 10:38 AM
finance.yahoo.com logoAeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
finance.yahoo.com - April 19 at 10:38 AM
finance.yahoo.com logoAeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
finance.yahoo.com - April 11 at 8:59 AM
finance.yahoo.com logoAeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
finance.yahoo.com - March 29 at 10:45 AM
morningstar.com logoAeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency | Morningstar
morningstar.com - March 23 at 11:42 PM
finance.yahoo.com logoAeterna Zentaris Says Enrollment In Growth Hormone Deficiency Trial To Continue Into 2023
finance.yahoo.com - March 21 at 4:17 PM
finance.yahoo.com logoSynlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 17 at 3:58 PM
seekingalpha.com logoAeterna Zentaris expands research program for COVID-19/Chlamydia vaccines
seekingalpha.com - March 10 at 8:59 AM
finance.yahoo.com logoAeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
finance.yahoo.com - March 10 at 8:59 AM
finance.yahoo.com logoAeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
finance.yahoo.com - January 20 at 10:35 AM
nz.finance.yahoo.com logoCompanies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth
nz.finance.yahoo.com - December 25 at 10:00 AM
seekingalpha.com logoAeterna Zentaris names new finance chief
seekingalpha.com - December 24 at 1:39 AM
seekingalpha.com logoAeterna Zentaris names new finance chief
seekingalpha.com - December 24 at 1:39 AM
finance.yahoo.com logoAeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
finance.yahoo.com - November 4 at 7:28 PM
sg.finance.yahoo.com logoAeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
sg.finance.yahoo.com - October 28 at 12:55 AM
finance.yahoo.com logoAeterna Zentaris (TSE:AEZS) shareholders have endured a 82% loss from investing in the stock five years ago
finance.yahoo.com - September 26 at 9:49 AM
finance.yahoo.com logoAeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 5:57 PM
finance.yahoo.com logoAeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
finance.yahoo.com - August 4 at 6:29 PM
uk.finance.yahoo.com logoAEZS Jul 2021 3.000 put
uk.finance.yahoo.com - July 16 at 7:54 PM
finance.yahoo.com logoWe Think Aeterna Zentaris (TSE:AEZS) Can Easily Afford To Drive Business Growth
finance.yahoo.com - June 28 at 8:59 AM
finance.yahoo.com logoHedge Funds Are Buying AEterna Zentaris Inc. (AEZS)
finance.yahoo.com - June 13 at 2:30 PM
finance.yahoo.com logoAeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
finance.yahoo.com - June 7 at 11:50 AM
finance.yahoo.com logoAeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
finance.yahoo.com - June 3 at 9:33 AM
ca.finance.yahoo.com logoStocks in play: Aeterna Zentaris Inc.
ca.finance.yahoo.com - May 19 at 1:45 PM
finance.yahoo.com logoAeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis
finance.yahoo.com - May 17 at 5:19 PM
finance.yahoo.com logoAeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
finance.yahoo.com - May 17 at 12:18 PM
finance.yahoo.com logoAeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis
finance.yahoo.com - May 13 at 1:15 PM
finance.yahoo.com logoAeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
finance.yahoo.com - May 13 at 8:11 AM
finance.yahoo.com logoAeterna Zentaris to Present at the Q2 Virtual Investor Summit
finance.yahoo.com - May 10 at 8:54 AM
finance.yahoo.com logoAeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
finance.yahoo.com - May 6 at 11:26 AM
finance.yahoo.com logoAeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
finance.yahoo.com - May 5 at 6:16 PM
finance.yahoo.com logoAeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
finance.yahoo.com - May 5 at 8:15 AM
finance.yahoo.com logoAeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
finance.yahoo.com - May 3 at 12:54 PM
finance.yahoo.com logoAeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
finance.yahoo.com - April 28 at 9:35 AM
msn.com logoWhy Is It Moving? Analyzing The Upward Movement in Aeterna Zentaris's Stock Today
msn.com - April 26 at 3:32 PM
finance.yahoo.com logoAEterna Zentaris Stock Shows Every Sign Of Being Significantly Overvalued
finance.yahoo.com - April 13 at 7:33 AM
finance.yahoo.com logoShould Aeterna Zentaris (TSE:AEZS) Be Disappointed With Their 100% Profit?
finance.yahoo.com - March 30 at 8:07 AM
finance.yahoo.com logoAeterna Zentaris: Q4 Earnings Snapshot
finance.yahoo.com - March 25 at 9:50 AM
finance.yahoo.com logoAeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 25 at 9:50 AM
msn.com logoAnalyzing The Price Action In AEterna Zentaris Stock Today
msn.com - March 15 at 2:51 PM
finance.yahoo.com logoAeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate
finance.yahoo.com - March 15 at 2:51 PM
finance.yahoo.com logoAeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
finance.yahoo.com - March 15 at 9:51 AM
Get Aeterna Zentaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:AEZS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.